A Negative THC Blood Sample Was Followed by Positives During Monitored Abstinence

A negative whole-blood THC sample did not necessarily mark the end of detectable THC in a monitored-abstinence study. Some participants produced later positive specimens while residing under continuous surveillance, so a negative-to-positive sequence alone could not establish new use.

The collection history was controlled

Karschner and colleagues studied 25 frequent, long-term cannabis users on a secure research unit. Whole blood was collected at admission and generally each morning over seven days. The THC quantification limit was 0.25 ng/mL.

Among the 16 participants with at least one positive specimen, two were below the quantification limit at admission but had a later positive. One participant had negative results at admission and on day three, with positives on several intervening and subsequent days.

A reporting boundary is not complete elimination

Below-quantification and positive results describe measurements relative to a method’s reporting boundary. They do not establish that all THC disappeared and then re-entered the body. The authors discussed variable release from tissue stores as a possible contributor, rather than experimentally isolating one mechanism.

This finding does not mean every negative-to-positive sequence is residual exposure. It supplies a documented alternative under the study conditions that must be considered before attributing a sequence to new consumption.

Keep the scope narrow

The study involved whole blood and selected heavy users. Its pattern should not be transferred automatically to urine, occasional use or another laboratory threshold. It also did not measure driving performance alongside each specimen.

A sequence interpretation needs collection times, assay limits and exposure history. The laboratory pattern and the inference about conduct remain separate questions.

Related: Separating cannabis exposure from impairment.

Research cited

Karschner EL; Schwilke EW; Lowe RH; et al.. Addiction (2009). Do delta-9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

An Open-Label CBD Dose-Escalation Study Could Not Establish Placebo-Adjusted Motor Benefit

A small open-label CBD dose-escalation study in Parkinson’s disease reported improved motor scores and frequent mild adverse effects. Those observations inform feasibility and tolerability, but do not establish how much improvement CBD produced beyond placebo or other influences. Escalation and completion were part of the design The review describes Leehey…

Spread the love

Read Article: An Open-Label CBD Dose-Escalation Study Could Not Establish Placebo-Adjusted Motor Benefit

An Isolated Naming Improvement Was Not a Global Cognitive Benefit in a CBD Trial

An improvement in one naming subdomain did not establish a general cognitive benefit in a Parkinson’s trial summarized by a review. Most other clinical and cognitive findings did not show the same favorable pattern. The preparation and population were specific The review describes Mitarnun and colleagues’ placebo-controlled trial of a…

Spread the love

Read Article: An Isolated Naming Improvement Was Not a Global Cognitive Benefit in a CBD Trial

Preserved Dopamine Neurons Did Not Mean Every Motor Test Improved After CBD

A CBD rat study summarized in a review reported neuronal protection and improvement in selected motor measures, with limited improvement on other tests. A tissue finding should therefore not be substituted for a universal functional benefit. The lesion model assessed several domains The review describes Giuliano and colleagues’ work in…

Spread the love

Read Article: Preserved Dopamine Neurons Did Not Mean Every Motor Test Improved After CBD

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us